EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within the EU Between 2011 and 2020

Robert Ancuceanu, Doina Drăgănescu, Beatrice Elena Lascu, Mihaela Dinu

Journal of Pharmaceutical and BioTech Industry · 25.06.2026 · 3 (3) · 15

DOI: 10.3390/jpbi3030015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical and BioTech Industry, online erschienen am 25.06.2026. Verfasst von Robert Ancuceanu und 3 weiteren Autor:innen. Die Arbeit nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmaceutical innovation plays a vital role in advancing global health. This study evaluates the landscape of pharmaceutical innovation in the European Union (EU) over the 2011–2020 decade.

Methods

A retrospective analysis was performed on new medicinal products containing new active substances (NAS) authorized between 2011 and 2020 through the centralized procedure. Products were categorized into first-in-class, advance-in-class, and addition-to-class. Trends in therapeutic areas (ATC codes), orphan designation, technology platforms, administration routes, and dosage forms were analyzed.

Results

Across the decade, 357 new medicinal products received authorization. Of these, 56% were designated as first-in-class and 28% as advance-in-class, indicating that 84% of new products contributed substantive therapeutic innovation. Small molecules remained the predominant technology (63.5%), yet the decade also witnessed a pronounced expansion in monoclonal antibodies and the introduction of cell and gene therapies (Advanced Therapy Medicinal Products, ATMPs). The increased use of subcutaneous delivery systems, particularly for monoclonal antibodies, suggests a broader shift toward patient-centered administration routes.

Conclusions

Between 2011 and 2020, pharmaceutical innovation in the European Union (EU) was characterized by a high rate of breakthrough innovations and a transition to more sophisticated biologic therapies. The EU could boost innovation further by refining expedited approval pathways (e.g., PRIME).

Zitieren

APA

Ancuceanu, R., Drăgănescu, D., Lascu, B. E., & Dinu, M. (2026). A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within the EU Between 2011 and 2020. Journal of Pharmaceutical and BioTech Industry, 3(3), 15. https://doi.org/10.3390/jpbi3030015

Vancouver

Ancuceanu R, Drăgănescu D, Lascu BE, Dinu M. A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within the EU Between 2011 and 2020. Journal of Pharmaceutical and BioTech Industry. 2026;3(3):15. doi:10.3390/jpbi3030015

BibTeX
@article{Ancuceanu2026,
  author = {Ancuceanu, Robert and Drăgănescu, Doina and Lascu, Beatrice Elena and Dinu, Mihaela},
  title = {A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within the EU Between 2011 and 2020},
  journal = {Journal of Pharmaceutical and BioTech Industry},
  year = {2026},
  volume = {3},
  number = {3},
  pages = {15},
  doi = {10.3390/jpbi3030015}
}
Kostenlos starten →